Madorra Enrolls First Patient in Pivotal Trial for Treatment of Moderate to Severe Vulvovaginal Atrophy: The WAVES Study
Breakthrough Device-Designated Therapy System Takes Important Step Toward Market Authorization
PORTLAND, OR, UNITED STATES, March 24, 2026 /EINPresswire.com/ — Madorra Inc., a medical device company developing innovative solutions for menopause-related conditions, today announced the enrollment of the first patient in its pivotal clinical trial, The Pivotal IDE Study of the Madorra Therapy System in Women with A Diagnosis of Vulvovaginal Atrophy to Evaluate Effectiveness and Safety (The WAVES Study), evaluating the Madorra Therapy System for the treatment of moderate to severe vulvovaginal atrophy (VVA), a component of genitourinary syndrome of menopause (GSM).
The pivotal trial represents a significant milestone for Madorra following the FDA’s grant of Breakthrough Device Designation.
